WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment of five internationally recognized scientists, entrepreneurs and visionary thinkers to its newly formed Scientific Advisory Board (SAB). The SAB includes: Peter G. Schultz, PhD (President of the Scripps Research Institute and the California Institute for Translational Research); James Larrick, MD and PhD (Founder, Managing Director, Scientific Director of Panorama Research Institute; Managing Director & Chief Medical Officer of Velocity Pharmaceutical Development); Ram Sasisekharan, PhD (Alfred H. Caspary Professor of Biological Engineering and Health Sciences & Technology at the Massachusetts Institute of Technology); David D. Ho, MD (Scientific Director and CEO, Aaron Diamond AIDS Research Center; and Irene Diamond Professor, the Rockefeller University) and Wei-Shou Hu, PhD (Distinguished McKnight University Professor at University of Minnesota).
Chaired by Dr. Schultz, the inaugural members represent a broad range of scientific disciplines in biologics research and development in the fields of synthetic biology, antibody therapeutics, protein engineering, analytical sciences, virology, vaccines, and cell culture bioprocessing and bioengineering. In addition, the SAB members are also thought leaders and entrepreneurs, collectively founding more than forty successful biotech companies.
The first SAB meeting was held on January 5, 2018 in San Diego. The SAB members thought highly of WuXi Biologics' achievements, business model, technology platforms, capabilities and capacities. "I am excited about the capabilities WuXi Biologics is building and the impact this will have on biologics in the healthcare industry," said Dr. Peter G. Schultz. The members offered many insightful strategic, tactical, and technical suggestions at the meeting to help guide the future business strategies at WuXi Biologics.
"This SAB will help shape the technological and strategic direction of the company and build additional momentum for WuXi Biologics' quest to transform the way in which biologics are discovered, developed and manufactured," said Dr. Chris Chen, CEO of WuXi Biologics. "The SAB will support WuXi Biologics' mission of becoming a technology leader and a trusted partner for biopharmaceutical companies worldwide to advance the science and technology of biologics development and ultimately benefiting patients worldwide."
Brief biographies of the SAB members are listed below.
Peter G. Schultz, PhD, SAB Chair
Dr. Peter Schultz is President of The Scripps Research Institute and The California Institute for Translational Research.
Dr. Schultz received his PhD from California Institute of Technologies and has a long distinguished academic career as professors of University of California at Berkeley and Scripps. Dr. Schultz founded the Genomics Institute of the Novartis Research Foundation and the California Institute for Biomedical Research, is a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies, and pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine. Dr. Schultz received numerous awards and has co-authored over 600 scientific publications. Dr. Schultz is a member of the National Academy of Sciences and the National Academy of Medicine.
James Larrick, MD/PhD
Dr. James Larrick is Founder, Managing Director, Scientific Director of Panorama Research Institute and Managing Director & Chief Medical Officer of Velocity Pharmaceutical Development.
Dr. Larrick holds MD and PhD degrees from Duke University School of Medicine and is a pioneer of the biotechnology industry. He is an outstanding biomedical entrepreneur with an international reputation in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development. He has written or coauthored eight books, over 250 papers/chapters, over 30 patents, and served on the editorial boards of six journals. In 1991, Jim founded the Panorama Institute of Molecular Medicine (PRI) which has incubated more t...
(All Rights Reserved)